NAS10031,224+0.48%S&P7,819+0.58%GOLD$4,143−1.05%BTC$83,746−2.12%VIX15.63+4.13%live tape · as of 11:02 UTC
The Screen · Basic Materials · Specialty Chemicals
Ingevity Corporation
NGVT · the NYSE · USD · Market cap $2.5B · 1,400 employees
Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America.
FAIL · Does not pass the screen
72.41 USD
Screen close, 2026-10-02 · not a live quote Last reviewed 5 days ago
Screened 2026-10-02 · the tape above runs as of 11:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 72.41 against the desk's fair-value range, base estimate 70.41, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price72.41 USD
Fair value70.41
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Accumulation68.96+5.0% to today ✓
2026-09-06Read Markdown69.56+4.1% to today
2026-08-06Read Accumulation76.53-5.4% to today
2026-07-02Read Distribution71.98+0.6% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ingevity Corporation holds its Accumulation at $72.41. The statistical read favours the sellers, held for 118 days.
As held on the ledger · 2026-10-02
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 118 days
Price at the screen
$72.41
Valuation
101.99 trailing · 12.04 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.17
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
75.26%
Below 33%
Interest-bearing debt is 75.3% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
12.43%
Below 49%
Money owed to the company is 12.4% of assets, under the 49% limit.
Pass
Revenue purity
0.38%
Below 5%
Only 0.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Ingevity's business is in a permissible area, but its interest-bearing debt is about 75% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-07. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-02 screen. The gold marker is the market price at the same screen. The price runs 2.8% above the base estimate.
Third-party analyst targets: 3 covering, consensus None. The average target sits +24% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Chemicals look cheap until the cycle turns
Picture a plant running flat out one quarter and idling the next. Orders for activated carbon and specialty additives swing with auto builds and oilfield work. Ingevity sits right in that swing. Revenue edges up only 4 percent while the firm posts an 11 percent loss and negative 114 percent return on equity. The 12.9 times forward earnings multiple looks low, yet peak-cycle earnings often produce exactly this picture. We pass.
The market prices the shares above our fair value and the three analysts who still cover it offer no consensus. Ethical checks clear, but that does not change the arithmetic. In a cyclical business a depressed multiple is usually a warning, not a bargain.
Margins can stay negative for longer than investors expect when end markets stay soft. Currency moves and raw-material spikes add further pressure. No moat rating changes the outlook. Analysis, not advice.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NGVT trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 54%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (4 analysts) rates it none, with a mean price target of $86. Insiders have been net sellers over the past quarter.
2026-09-06Markdown · changed$69.56-9.1%Entry 5
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 54%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (4 analysts) rates it none, with a mean price target of $86. Insiders have been net sellers over the past quarter.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 54%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (4 analysts) rates it none, with a mean price target of $86.
2026-07-18Distribution$71.98+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 54%. Our forward projection puts the odds of a 10% gain over the next month near 31%. The street (4 analysts) rates it none, with a mean price target of $86.
2026-07-03Distribution$71.98+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$71.98Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
